SEC Form 4 · accession 0001209191-17-055918
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Oct 2, 2017
Accepted (ET)
Oct 4, 2017 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 2, 2017 | M | 3,437 | $73.51 | A | 117,861 | D | |
| Common StockF2,F3 | Oct 2, 2017 | S | 1,394 | $151.04 | D | 116,467 | D | |
| Common StockF3,F4 | Oct 2, 2017 | S | 1,443 | $151.82 | D | 115,024 | D | |
| Common StockF3,F5 | Oct 2, 2017 | S | 600 | $152.62 | D | 114,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $73.51 | Oct 2, 2017 | M | 3,437 | D | — | Jan 1, 2024 | Common Stock | 3,437 | 3,438 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $151.04 (range $150.37 to $151.36).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $151.82 (range $151.47 to $152.18).
- F5Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.54 to $152.70).
- F6The option vests in 16 quarterly installments from 1/2/2014.